|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Costs and expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Asset impairment loss | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Interest expense | |||||
| Interest expense, net | |||||
| Write-off related party note receivable | |||||
| Change in fair value of contingent consideration and derivative financial instruments | |||||
| Inducement expense | |||||
| Loss before income taxes | |||||
| Income tax benefit (expense) | |||||
| Net loss | |||||
| Deemed dividend (see Note 4) | |||||
| Net loss available to common stockholders, basic | |||||
| Weighted-average common shares outstanding basic | |||||
| Weighted-average common shares outstanding diluted | |||||
| Net loss per common share basic | |||||
| Net loss per common share diluted | |||||
Loading...